Recent Updates — PHAR
Pharming Group reported third-quarter total revenues of US$117.6 million, a 21% increase year-over-year that exceeded market expectations. RUCONEST sales rose 14% to US$93.8 million as U.S. demand stabilized, while Joenja revenue surged 58% to US$23.8 million driven by international launches and strong U.S. uptake. Operating profit nearly doubled to US$29.9 million, up 89%, supported by higher sales and favorable foreign exchange movements. The company tightened its full-year revenue guidance to a range of US$380 million to US$390 million. Additionally, Pharming announced positive Phase II data for leniolisib in genetically identifiable primary immunodeficiencies and expects further CVID trial results in November 2026. Pharming Group N.V. is a global biotechnology company that develops and commercializes innovative medicines for people living with rare immune and genetic diseases.
Pharming Group N.V. reports preliminary third-quarter 2026 total revenues of approximately US$117.6 million, a 21% increase from the prior-year period, driven by strong performance in RUCONEST and Joenja. The company has tightened its full-year 2026 revenue guidance to between US$380 million and US$390 million, up from the previous range of $375 million to $395 million, while lowering operating expense guidance. Full financial results will be reported on October 27, 2026. Pharming Group N.V. is a global biotechnology company that develops and commercializes innovative medicines for rare immune and genetic diseases.
Pharming Group N.V. presented positive topline data from a single-arm, open-label Phase II trial of leniolisib in patients with genetically identifiable primary immunodeficiencies (PIDs) linked to altered PI3Kδ signaling. The study enrolled 13 participants across four genotypes (CTLA4, SOCS1, NFKB1, FAS), nine of whom also had common variable immunodeficiency (CVID). Leniolisib was well-tolerated with no new safety signals. Key efficacy results included a mean spleen volume reduction of 26.4% in evaluable participants and a mean lymph node size reduction of 33.7%. Pulmonary function improved, with DLCO increasing by 8.0%, and liver stiffness improved in two of three participants. All 12 completers enrolled in a long-term extension study. The data support the potential of targeted PI3Kδ inhibition to address immune dysregulation beyond APDS. Pharming Group N.V. is a global biotechnology company that develops and commercializes innovative medicines for rare immune and genetic diseases.
Pharming Group N.V. announced on September 29, 2026, that CEO Fabrice Chouraqui has stepped down with immediate effect following a mutual agreement due to misalignment on strategic priorities. The Board appointed Chief Commercial Officer Leverne Marsh and Chief Financial Officer Kenneth Lynard as Interim Co-CEOs to ensure leadership continuity while a formal search for a permanent successor begins. Marsh will lead patient-focused operations, while Lynard oversees global corporate functions. The company affirmed that its strategy, pipeline, and commitment to patients remain unchanged. Pharming Group N.V. is a global biotechnology company focused on developing and commercializing innovative medicines for rare immune and genetic diseases.
Pharming Group N.V. announced that the U.S. Food and Drug Administration has accepted its supplemental New Drug Application for lower doses of Joenja (leniolisib) to treat children aged 4 years and older with activated phosphoinositide 3-kinase delta syndrome who weigh between 13 kg and 27 kg. The application received Priority Review designation, establishing a Prescription Drug User Fee Act target action date of January 30, 2027. This expansion follows the September 2026 approval for children aged 4 to 11 years weighing at least 27 kg. Pharming Group N.V. is a global biotechnology company that develops and commercializes innovative medicines for rare immune and genetic diseases.
Pharming Group N.V. announced that a late-breaking abstract highlighting positive topline data from its Phase II trial with leniolisib in genetically identifiable primary immunodeficiencies (PIDs) with immune dysregulation has been accepted at the ESID 2026 conference. The single-arm, open-label study evaluated safety and efficacy in 13 subjects, demonstrating a favorable safety profile and clinical improvements including a mean 26.4% spleen volume reduction. Nine of the enrolled patients also had common variable immunodeficiency (CVID). Pharming expects to report topline results from a separate Phase II trial of leniolisib in CVID patients during the fourth quarter of 2026. Pharming Group N.V. is a global biotechnology company that develops and commercializes innovative medicines for people living with rare immune and genetic diseases.